(14) A recent phase 1/2 trial conducted at our center demonstrated encouraging response rates and an acceptable safety profile, underscoring the potential of dual-target CAR (CD19/20) T-cell therapy in patients with refractory or relapsed DLBCL. Here, CD19 is linked to diffuse large B-cell lymphoma.